Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljae444 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von John T Lear und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Manchester Royal Infirmary, Manchester, UK. Hauptthemen laut MEDLINE: Basal Cell Nevus Syndrome, Hedgehog Proteins, Skin Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: PellePharm, Inc..
Abstract (Originalsprache)
Background
Patients with Gorlin (basal cell naevus) syndrome (GS) have numerous phenotypic abnormalities due to overactivity of the hedgehog (HH) signalling pathway, most commonly caused by a heritable mutation in PTCH1, which encodes a major inhibitor of this pathway. Oral HH inhibitors (HHi) can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit–risk ratio, we developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop oral HHi treatment.
Objectives
To determine whether or not patidegib topical gel 2% or 4% can accumulate in high enough concentrations to have local anti-BCC efficacy but not so high that systemic drug levels produce the adverse effects typical of oral HHi treatment.
Methods
We conducted a small randomized double-blinded phase IIA trial at two sites in the UK, to assess the clinical and molecular efficacy and adverse effects of 6 months of twice-daily application of patidegib topical gel to the entire face, as well as to treatment-targeted surgically eligible BCCs at other anatomical sites.
Results
Post hoc analyses suggested that patidegib topical gel reduced the number of new, surgically eligible BCCs and the level of HH signalling, with minimal adverse effects.
Conclusions
Patidegib topical gel warrants further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Manchester Royal Infirmary, Manchester, UK.
- Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
- Royal London Hospital, Barts Health NHS Trust/Queen Mary University of London, London, UK.
- PellePharm, Inc., San Francisco, CA, USA.
- Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
ORCID-Profile: Gerd G Kochendoerfer
Förderung
- PellePharm, Inc.
Zitieren
APA
Lear, J. T., Harwood, C. A., Hasan, Z., Kentley, J., Thomson, J., Khoo, A., Alderman, A., DeSouza, M., Epstein, E. H., Kochendoerfer, G. G., & Tang, J. Y. (2025). Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae444
Vancouver
Lear JT, Harwood CA, Hasan Z, Kentley J, Thomson J, Khoo A, et al. Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae444
BibTeX
@article{Lear2025,
author = {Lear, John T and Harwood, Catherine A and Hasan, Zeeshaan and Kentley, Jonathan and Thomson, Jason and Khoo, Andre and Alderman, Alix and DeSouza, Mark and Epstein, Ervin H and Kochendoerfer, Gerd G and Tang, Jean Y},
title = {Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljae444}
}
EUVIMED